Envestnet Asset Management
TPTX

Envestnet Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Envestnet Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,954
Closed -$448K – 4100
2022
Q2 		$448K Buy
+5,954
New +$265K ﹤0.01% 3112
2022
Q1 		– Sell
-5,106
Closed -$244K – 4105
2021
Q4 		$244K Buy
5,106
+1,443
+39% +$64.5K ﹤0.01% 3543
2021
Q3 		$243K Buy
3,663
+287
+9% +$20.4K ﹤0.01% 3412
2021
Q2 		$263K Buy
3,376
+238
+8% +$17.6K ﹤0.01% 3366
2021
Q1 		$297K Sell
3,138
-475
-13% -$56.5K ﹤0.01% 3139
2020
Q4 		$440K Buy
3,613
+322
+10% +$35.3K ﹤0.01% 2726
2020
Q3 		$288K Buy
+3,291
New +$229K ﹤0.01% 2748

Envestnet Asset Management's TPTX Position: Q3 2022 in Review

Envestnet Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 5,954 shares — an estimated $448K sold.

Envestnet Asset Management first reported a position in TPTX in Q3 2020 and held it in 7 quarters. The position peaked at $448K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Envestnet Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Envestnet Asset Management sold 5,954 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $448K.
  • Envestnet Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
  • Envestnet Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $448K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Envestnet Asset Management's 13F filing for Q3 2022, filed 10 Nov 2022.